Travecta Therapeutics

Background

SPRIM Global Investments exited in 2021. Travecta is a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions by utilizing a natural transport system in the blood-brain barrier (“BBB”) as a novel delivery platform.